Table 2 Summary of the clinical characteristics, RNA quality and cDNA preamplification results for the 22 samples analyzed in this study.
Sample number | Type of sample | Type of bladder fluid | Tumor characteristics | RNA characteristics | N° validated genes (CT ≤ 31) | Correlation coeficients (r) | N° validated genes in NPA samples with ΔΔCT outside ± 1.5 | Gene symbol | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
rRNA ratio | RIN | % of total | |||||||||||
stage | grade | 18S area | 28S area | NPA samples | PA samples | ||||||||
1 | T | BW | Ta | LG | 2 | 9.8 | 20.6 | 40.4 | 33 | 43 | 0.986 | 1 | IGF2 |
2 | T | BW | Ta | LG | 1.7 | 9.2 | 18.5 | 31.6 | 39 | 46 | 0.978 | 4 | CRH, FGFR3, IGF2,KRT14 |
3 | T | BW | Ta | LG | 1.7 | 8.9 | 18.5 | 32.1 | 38 | 45 | 0.987 | 2 | CRH,IGF2 |
4 | T | BW | Ta | LG | 1.6 | 8.8 | 17.0 | 26.8 | 36 | 45 | 0.991 | 1 | IGF2 |
5 | T | BW | Ta | LG | 1.3 | 8.2 | 14.2 | 18.1 | 25 | 42 | 0.987 | 1 | IGF2 |
6 | T | BW | T2b+CIS | HG | 1.8 | 8 | 9.3 | 16.7 | 38 | 44 | 0.967 | 3 | CCNA2, IGF2, MAGEA9 |
7 | T | BW | T1 | HG | 2.3 | 7.8 | 8.1 | 18.7 | 35 | 43 | 0.975 | 3 | FGFR3, IGF2, MELK |
8 | C | BW | - | - | 1.5 | 7.6 | 8.6 | 12.6 | 19 | 40 | 0.985 | 0 | - |
9 | T | BW | T1c | HG | 1.6 | 7.5 | 9.4 | 15.0 | 32 | 42 | 0.98 | 5 | FGFR3, IGF2, KIF2C, MELK, PDZRN3 |
10 | T | U | T1c+CIS | HG | 1.1 | 7.5 | 13.6 | 15.0 | 40 | 45 | 0.961 | 2 | CRH, IGF2 |
11 | T | U | T1b | HG | 0.8 | 7.5 | 12.8 | 10.1 | 41 | 46 | 0.956 | 3 | CRH, FGFR3, IGF2 |
12 | T | U | T1 | HG | 1.2 | 7.4 | 10.5 | 12.3 | 39 | 45 | 0.972 | 2 | CRH, IGF2 |
13 | C | BW | - | - | 1.3 | 7.2 | 7.9 | 10.0 | 28 | 39 | 0.976 | 1 | IGF2 |
14 | T | BW | T1+CIS | HG | 1.3 | 6.4 | 6.4 | 8.4 | 35 | 43 | 0.975 | 3 | CRH, FGFR3, IGF2 |
15 | C | BW | - | - | 0.8 | 2.8 | 1,6 | 1,3 | 3 | 13 | 0.937 | 0 | _ |
16 | C | U | - | - | 0 | 2.5 | N/A | N/A | 8 | 14 | 0.95 | 1 | KRT14 |
17 | T | U | T2 | HG | 0 | 2.5 | N/A | N/A | 11 | 39 | 0.994 | 1 | CDC2 |
18 | T | U | T1 | HG | 0 | 2.4 | N/A | N/A | 13 | 41 | 0.965 | 3 | GJB2, FGFR3, IGF2 |
19 | T | U | T2+CIS | HG | 0 | 2.4 | N/A | N/A | 27 | 40 | 0.97 | 5 | CCNA2, CRH, FGFR3, IGF2, KRT14 |
20 | T | U | T2+CIS | HG | 0 | 2.3 | N/A | N/A | 31 | 45 | 0.938 | 2 | IGF2, TOP2A |
21 | C | BW | - | - | 1.3 | N/A | 3.8 | 4.6 | 18 | 36 | 0.943 | 2 | IGF2, FGFR3 |
22 | T | BW | T2b | HG | 1.1 | N/A | 8.6 | 9.4 | 40 | 45 | 0.968 | 1 | IGF2 |